Idiosyncratic drug-induced liver injury (iDILI) encompasses the unexpected harms that
prescription and non-prescription drugs, herbal and dietary supplements can cause to the …

Drug-induced liver injury (DILI) is a major clinical problem in terms of patient morbidity and
mortality, cost to healthcare systems and failure of the development of new drugs. The need …

Predicting drug-induced liver injury in a preclinical setting remains challenging, as cultured
primary human hepatocytes (PHHs), pluripotent stem cell-derived hepatocyte-like cells …

Reliable and versatile hepatic in vitro systems for the prediction of drug pharmacokinetics
and toxicity are essential constituents of preclinical safety assessment pipelines for new …

Recent advances in pluripotent stem cell technology provide an alternative source of human
hepatocytes to overcome the limitations of current toxicity tests. However, this approach …

Assessing the potential of a new drug to cause drug-induced liver injury (DILI) is a challenge
for the pharmaceutical industry. We therefore determined whether cell models currently used …

Drug-induced liver injury (DILI) remains a major cause of drug development failure, post-
marketing warnings and restriction of use. An improved understanding of the mechanisms …

Salcaprozate sodium (SNAC) and sodium caprate (C 10) are the two leading intestinal
permeation enhancers (PEs) in oral peptide formulations in clinical trials. There is debate …

Toxicity is an important factor in failed drug development, and its efficient identification and
prediction is a major challenge in drug discovery. We have explored the potential of …

Drug‐induced liver injury (DILI) is a major cause of drug attrition. Testing drugs on human
liver models is essential to mitigate the risk of clinical DILI since animal studies do not …